Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | MLYCD | O95822 | 2/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15553491 | 0.78 | TRPV4 (0.43) | HDAC4MRGPRX4TRPV4P2RX7GPBAR1 | |
| SCHEMBL4284245 | 0.77 | HDAC4 (0.44) | HDAC4NPSR1RXRARXRBALDH1A1 | |
| SCHEMBL2097683 | 0.76 | NPSR1 (0.48) | NPSR1ALDH1A1 | |
| SCHEMBL60214 | 0.75 | TAS2R14 (0.43) | P2RX7NPSR1RXRARXRBALDH1A1 | |
| SCHEMBL28036935 | 0.74 | ALDH1A1 (0.40) | NPSR1ALDH1A1 | |
| SCHEMBL1081803 | 0.73 | NPSR1 (0.41) | NPSR1ALDH1A1 | |
| SCHEMBL19778 | 0.73 | NPSR1 (0.70) | NPSR1TRPM8ALDH1A1 | |
| SCHEMBL2094545 | 0.72 | MEN1 (0.49) | NPSR1ALDH1A1 | |
| SCHEMBL1037769 | 0.72 | OXTR (0.56) | NPSR1ALDH1A1 | |
| SCHEMBL3759729 | 0.72 | MLYCD (0.42) | HDAC4MRGPRX4TRPV4P2RX7MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796272-B2 | Glycine transporter-inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130331571-A1 | GLYCINE TRANSPORTER-INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-12-12 | — | — | US | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331571-A1 | GLYCINE TRANSPORTER-INHIBITING SUBSTANCES | SLC1A2, SLC18A2, SLC6A1 | HDAC4 3438/4885MRGPRX4 1281/4885TRPV4 848/4885 |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | HDAC4 2659/4885MRGPRX4 2782/4885TRPV4 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.